Despite Soft Guidance, J&J Remains a Good Long-Term Buy

The blue-chip multinational has a good mix of prescription and over-the-counter products, which makes it well-suited to weather volatility. Shares of Johnson & Johnson sank 1.72% on Tuesday following softer-than-expected guidance for 2017.